drug
edoxaban tosylate
Marketedupdated 5mo agoby Daiichi Sankyo Co Ltd
Approvedcommunity read0 votes
indications
investigational
Atrial Fibrillation
all catalysts(0)
nothing on the calendar yet
Trials studying edoxaban tosylate
Patent cliff
source: FDA Orange Bookfirst barrier falls
Oct 18, 2026
16 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (6)
- Mar 28, 2028formulationUS 91495321.5y
- Mar 28, 2028formulationUS 91495321.5y
- Mar 28, 2028formulationUS 91495321.5y
- Apr 18, 2027compositionUS 7365205198d
- Apr 18, 2027compositionUS 7365205198d
- Apr 18, 2027compositionUS 7365205198d
FDA exclusivities (3)
- Oct 18, 2026M-14Method (3y)16d
- Oct 18, 2026M-14Method (3y)16d
- Oct 18, 2026M-14Method (3y)16d
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 2h ago
Found something off?
comments(0)
5-min edit window · permanent after that